<?xml version="1.0" encoding="UTF-8"?>
<list>
  <sentences>
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="50474" end="50481" sStart="-1" offset="0" sid="null" wn="2" wnkey="write%2:32:00::" text="Dr. Rich contributed to &lt;b&gt;writing&lt;/b&gt; the portion of the manuscript that refers to the statistical analytical plan." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="38994" end="39001" sStart="null" offset="0" sid="null" wn="2" wnkey="write%2:32:00::" text="&lt;b&gt;Written&lt;/b&gt; informed consent is obtained for every study subject." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="20116" end="20120" sStart="null" offset="83" sid="r7.1.use.v.0269" wn="1" wnkey="use%2:34:01::" text="The clinical coordinator also constructs the abstracted medical record used for subtyping of the index stroke by copying admission notes, physician progress notes, discharge summaries, radiology reports, electrocardiograms, echocardiography reports, laboratory reports, and rehabilitation notes." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="36167" end="36172" sStart="null" offset="83" sid="r7.1.use.v.0414" wn="1" wnkey="use%2:34:01::" text="Power for any analyses involving continuous measures can be approximated using an independent t test comparison between the incident cases and controls." />
    <s path="file:/c:/OANC/data/written_2/technical/biomed/1471-2377-3-4.anc" start="14977" end="14981" sStart="null" offset="0" sid="null" wn="7" wnkey="time%1:28:03::" text="If the patient awoke with stroke symptoms, the &lt;b&gt;time&lt;/b&gt; of onset is taken as the last &lt;b&gt;time&lt;/b&gt; the patient was &lt;b&gt;known&lt;/b&gt; to be awake and without any symptoms of stroke." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="4749" end="4758" sStart="null" offset="68" sid="r8.suggest.v.0188" wn="3" wnkey="suggest%2:32:02::" text="[ 12 ] on the G448A polymorphism of the ?-fibrinogen gene suggested that mechanisms linking fibrinogen and the development of cerebrovascular disease may be different in men and women." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="46219" end="46225" sStart="null" offset="352" sid="r11.severe.j.0064" wn="1" wnkey="severe%5:00:00:intense:00" text="For example, in one study of intra-arterial thrombolysis for treatment of acute ischemic stroke, 12,323 patients with stroke were screened, and only 180 patients were selected [ 4 ] . Other stroke studies include only patients with nondisabling strokes [ 52 ] , or include only patients with moderate to severe strokes [ 4 ] . Because ISGS is a dedicated stroke genetic association study, it has broad eligibility criteria relative to clinical trials of drugs or devices." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="39306" end="39312" sStart="null" offset="242" sid="r11.severe.j.0055" wn="1" wnkey="severe%5:00:00:intense:00" text="To the extent permitted by local IRBs, surrogate consent is permitted for patients rendered incompetent by stroke to avoid biasing the study toward discovery of risk factors for mild or moderate stroke but not severe stroke." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="17134" end="17140" sStart="null" offset="720" sid="r11.severe.j.0357" wn="5" wnkey="severe%5:00:00:critical:03" text="We confirm that controls have not had a prior stroke by means of the Questionnaire for Verifying Stroke-free Status (QVSS), a structured interview that was validated in an adult population (age, &gt; 60 years) using systematic review of electronic medical records as the benchmark [ 25 ] . The QVSS was further validated in an independent population using history and physical examination by a study neurologist as the benchmark [ 26 ] . Interviewers administering the QVSS may exclude a subject they judge to be an unreliable historian on the basis of a global impression of moderate or severe impairment of speech, language, hearing, or memory." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="46219" end="46225" sStart="null" offset="352" sid="r11.severe.j.0064" wn="6" wnkey="severe%5:00:01:bad:00" text="For example, in one study of intra-arterial thrombolysis for treatment of acute ischemic stroke, 12,323 patients with stroke were screened, and only 180 patients were selected [ 4 ] . Other stroke studies include only patients with nondisabling strokes [ 52 ] , or include only patients with moderate to severe strokes [ 4 ] . Because ISGS is a dedicated stroke genetic association study, it has broad eligibility criteria relative to clinical trials of drugs or devices." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="39306" end="39312" sStart="null" offset="242" sid="r11.severe.j.0055" wn="6" wnkey="severe%5:00:01:bad:00" text="To the extent permitted by local IRBs, surrogate consent is permitted for patients rendered incompetent by stroke to avoid biasing the study toward discovery of risk factors for mild or moderate stroke but not severe stroke." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="50391" end="50396" sStart="null" offset="99" sid="r11.refer.v.0590" wn="1" wnkey="refer%2:32:01::" text="Dr. Hardy and Mr. Crook contributed to writing the portions of the manuscript that refer specifically to DNA sequencing and analysis." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="37356" end="37361" sStart="null" offset="0" sid="null" wn="1" wnkey="powerfulness%1:07:00::" text="For the African American group, we generally have &lt;b&gt;power&lt;/b&gt; for relatively high-frequency polymorphisms in controls (approximately 45%-50%) and detectable differences of 40% in cases (0." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="37637" end="37642" sStart="null" offset="0" sid="null" wn="6" wnkey="power%1:10:00::" text="Thus, we could detect an SNP allele frequency of 0.70 in cases and 0.45 in controls with 80% &lt;b&gt;power&lt;/b&gt;." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="37356" end="37361" sStart="null" offset="0" sid="null" wn="3" wnkey="power%1:09:01::" text="For the African American group, we generally have &lt;b&gt;power&lt;/b&gt; for relatively high-frequency polymorphisms in controls (approximately 45%-50%) and detectable differences of 40% in cases (0." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="37637" end="37642" sStart="null" offset="0" sid="null" wn="3" wnkey="power%1:09:01::" text="Thus, we could detect an SNP allele frequency of 0.70 in cases and 0.45 in controls with 80% &lt;b&gt;power&lt;/b&gt;." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="32754" end="32759" sStart="null" offset="0" sid="null" wn="2147483646" wnkey="null" text="Extending SNPs to haplotypes has the advantage of increased information, yet decreased &lt;b&gt;power&lt;/b&gt; in small samples due to the increased number of possible haplotypes to be tested." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="38318" end="38323" sStart="null" offset="0" sid="null" wn="2147483646" wnkey="null" text="For large interactions we have &gt; 99% statistical &lt;b&gt;power&lt;/b&gt;." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="14284" end="14292" sStart="null" offset="186" sid="r11.function.n.0269" wn="2" wnkey="function%1:07:00::" text="Stroke is defined according to the World Health Organization criteria [ 19 ] as rapidly developing signs of a focal or global disturbance of cerebral function with symptoms lasting 24 hours or longer or leading to death, with no apparent cause other than vascular origin." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="15953" end="15957" sStart="null" offset="0" sid="null" wn="1 6" wnkey="null" text="The logs will contain initials and &lt;b&gt;date&lt;/b&gt; of birth of the eligible stroke patients, &lt;b&gt;date&lt;/b&gt; of screening, sex, and race/ethnicity." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="15953" end="15957" sStart="null" offset="0" sid="null" wn="6" wnkey="date%1:28:03::" text="The logs will contain initials and &lt;b&gt;date&lt;/b&gt; of birth of the eligible stroke patients, &lt;b&gt;date&lt;/b&gt; of screening, sex, and race/ethnicity." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="15953" end="15957" sStart="null" offset="0" sid="null" wn="6" wnkey="date%1:28:03::" text="The logs will contain initials and &lt;b&gt;date&lt;/b&gt; of birth of the eligible stroke patients, &lt;b&gt;date&lt;/b&gt; of screening, sex, and race/ethnicity." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="15953" end="15957" sStart="null" offset="0" sid="null" wn="6" wnkey="date%1:28:03::" text="The logs will contain initials and &lt;b&gt;date&lt;/b&gt; of birth of the eligible stroke patients, &lt;b&gt;date&lt;/b&gt; of screening, sex, and race/ethnicity." />
    <s path="file:/D:/Corpora/oanc/data/written_2/technical/biomed/1471-2377-3-4.anc" start="15953" end="15957" sStart="null" offset="0" sid="null" wn="6" wnkey="date%1:28:05::" text="The logs will contain initials and &lt;b&gt;date&lt;/b&gt; of birth of the eligible stroke patients, &lt;b&gt;date&lt;/b&gt; of screening, sex, and race/ethnicity." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="45050" end="45058" sStart="null" offset="106" sid="r10.control.n.0925" wn="4" wnkey="control%1:09:02::" text="In a prevention study, DNA would be available both from patients with stroke and from stroke-free controls, but the intervention may alter the outcome (stroke) sufficiently to confound interpretation of the results of a genetic association study." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="24760" end="24767" sStart="null" offset="131" sid="r10.control.n.0473" wn="4" wnkey="control%1:09:02::" text="The study coordinator at the local center obtains two tubes of peripheral blood from each patient and each control subject, collected in a 10-mL (8." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="32350" end="32357" sStart="null" offset="316" sid="r10.control.n.0377" wn="4" wnkey="control%1:09:02::" text="Thus, initial analyses using members of the fibrinogen cluster (or with other candidate genes such as GPIb?) will focus on each case/control being classified by the presence of a risk allele (yes/no), with comparison of SNP allele frequencies between groups (stroke/control)." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="36697" end="36704" sStart="null" offset="82" sid="r10.control.n.0197" wn="4" wnkey="control%1:09:02::" text="The power is determined on the basis of the frequency of the SNP in the control group and the detectable difference in SNP allele frequency in the control group." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="48894" end="48902" sStart="null" offset="47" sid="r10.control.n.0568" wn="4" wnkey="control%1:09:02::" text="In addition, the stroke-free status of controls in ISGS and of discordant siblings in SWISS is verified using the same structured interview instrument (i.e." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="11656" end="11663" sStart="null" offset="13" sid="r10.control.n.0626" wn="4" wnkey="control%1:09:02::" text="Patients and control subjects are screened at one of five clinical centers (Appendix 1 - Additional file: 1), stroke status is verified, the index stroke for each patient is subtyped, and baseline clinical and demographic data are collected." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="30591" end="30599" sStart="null" offset="28" sid="r10.control.n.0522" wn="4" wnkey="control%1:09:02::" text="Cases will be compared with controls with respect to predictor variables of interest and with respect to genotypes that may provide increased risk for stroke." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="29302" end="29310" sStart="null" offset="59" sid="r10.control.n.0474" wn="4" wnkey="control%1:09:02::" text="Thus, patients with stroke will be compared with controls as to frequency and distribution of these polymorphisms." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="4556" end="4562" sStart="null" offset="78" sid="r10.common.j.0404" wn="4" wnkey="common%5:00:00:familiar:02" text="Abnormal results on carotid ultrasonography were significantly more common in the T/T genotype group (OR, 6.29; 95% CI, 1.91 to 20." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="38907" end="38913" sStart="null" offset="27" sid="r10.board.n.0913" wn="1" wnkey="board%1:14:00::" text="Local institutional review boards (IRBs) governing each clinical center have approved the study protocol." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="46919" end="46926" sStart="null" offset="415" sid="null" wn="1" wnkey="absence%1:26:00::" text="Additionally, we have given careful attention to appropriate selection of controls [ 27 ] . The controls are concurrently enrolled at the same centers as are the patients, and controls are also screened for a medical history of stroke or transient ischemic attack and for the presence of symptoms of stroke or transient ischemic attack which may have occurred in the absence of a corresponding medical history." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="46919" end="46926" sStart="null" offset="415" sid="null" wn="1" wnkey="absence%1:26:00::" text="Additionally, we have given careful attention to appropriate selection of controls [ 27 ] . The controls are concurrently enrolled at the same centers as are the patients, and controls are also screened for a medical history of stroke or transient ischemic attack and for the presence of symptoms of stroke or transient ischemic attack which may have occurred in the absence of a corresponding medical history." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="46919" end="46926" sStart="null" offset="415" sid="null" wn="1" wnkey="absence%1:26:00::" text="Additionally, we have given careful attention to appropriate selection of controls [ 27 ] . The controls are concurrently enrolled at the same centers as are the patients, and controls are also screened for a medical history of stroke or transient ischemic attack and for the presence of symptoms of stroke or transient ischemic attack which may have occurred in the absence of a corresponding medical history." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="46919" end="46926" sStart="null" offset="415" sid="r11.absence.n.0567" wn="1" wnkey="absence%1:26:00::" text="Additionally, we have given careful attention to appropriate selection of controls [ 27 ] . The controls are concurrently enrolled at the same centers as are the patients, and controls are also screened for a medical history of stroke or transient ischemic attack and for the presence of symptoms of stroke or transient ischemic attack which may have occurred in the absence of a corresponding medical history." />
    <s path="[OANC]/data/written_2/technical/biomed/1471-2377-3-4.anc" start="26087" end="26094" sStart="null" offset="46" sid="r11.absence.n.0381" wn="1" wnkey="absence%1:26:00::" text="All cell cultures are done in the absence of antibiotics." />
  </sentences>
</list>